Effect of B Vitamin (Folate, B6, and B12) Supplementation on Osteoporotic Fracture and Bone Turnover Markers: A Meta-Analysis

Jianwei Ruan, Xiaokang Gong, Jinsong Kong, Haibao Wang, Xin Zheng, Tao Chen

Corresponding Author: Haibao Wang, e-mail: tzslyygk@163.com

Source of support: This study was supported by the 2014 General Medical and Health Research Plan of Zhejiang Province, China, Grant No. 2014KYA229

Background: B vitamins (including folate, B6, and B12) supplementation can effectively and easily modify high plasma homocysteine (Hcy). However, the role of Hcy in the pathogenesis of osteoporotic fracture and bone turnover is still controversial. This meta-analysis aimed to assess the impact of B vitamin supplementation on occurrence of any osteoporotic fracture and bone turnover by pooling the results of previous studies.

Material/Methods: Relevant randomized controlled trials (RCTs) were searched in databases. Data integration and analysis were done by using Review Manager 5.3 (the Cochrane Collaboration). The risk ratio (RR) and corresponding 95% confidence intervals (CI) of fracture (intervention vs. control) were estimated. Changes in bone turnover indicators (continuous data), weighted mean difference (WMD), and corresponding 95% (CI) were pooled for estimation.

Results: Based on the results of 4 RCTs, this meta-analysis failed to identify a risk-reducing effect of daily supplementation of B vitamins on osteoporotic fracture in patients with vascular disease and with relatively normal plasma Hcy. In addition, we also did not find any positive effects of B vitamin supplementation on bone turnover.

Conclusions: B vitamin supplementation might not be effective in preventing fracture and improving bone turnover. However, the possible benefits in selective populations, such as populations with very high plasma Hcy and from regions without B vitamin fortification should be explored in the future.

MeSH Keywords: Fractures, Bone • Homocysteine • Meta-Analysis as Topic • Vitamin B Complex

Abbreviations: Hcy – homocysteine; WMD – weighted mean difference; BMD – bone mineral density; ALP – alkaline phosphatase; CTX – cross-linked C-telopeptide

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/893310
META-ANALYSIS

Background

Osteoporosis is a metabolic skeletal disorder characterized as decreased bone strength and significantly increased risk of fracture [1]. The most common osteoporotic fracture sites include hip, spine, and wrist. Particularly, spine and hip fractures are associated with poor outcomes, which usually require hospitalization and surgery [2,3]. In addition, these fractures also significantly increase the risk of disability, morbidity, and mortality [4]. Therefore, simple interventions that can delay the onset of osteoporosis or lower the risk of osteoporotic fracture are needed.

Plasma homocysteine (Hcy), which is formed by the demethylation of dietary methionine, has been postulated as a novel and potential risk factor of osteoporotic fractures [5]. High plasma total homocysteine levels are associated with accelerated bone loss in men and premenopausal women [6]. A large prospective study found that the population group with the highest quartile of total Hcy had 2 times higher risk of fracture [7]. A recent meta-analysis based on 14,863 patients also confirmed that all fracture risk of the highest Hcy quartile group compared with the lowest quartile group was 1.59 (95% CI 1.30–1.96) [8]. Although several studies have been performed to explore the relationship between Hcy and osteoporosis, it is still not clear whether the association is causal, confounded, or biased due to reverse causality [9,10].

B vitamin (including folate, B6, and B12) supplementation can effectively and easily modify high plasma Hcy [11,12]. Therefore, it is possible to determine whether thcy is a causal risk factor of bone fracture and how it affect bone metabolism in terms of bone turnover markers through comparing B-vitamins vs. placebo in randomized controlled studies (RCTs). In fact, several relevant RCTs were performed, but the results are conflicting. Due to uncertainties about the role of Hcy in pathogenesis of osteoporotic fracture and bone turnover, this meta-analysis aimed to assess the effect of B vitamin supplementation (folate, B6, and B12) on occurrence of any osteoporotic fractures and bone turnover by pooling results of previous studies.

Material and Methods

Searching and screening of studies

Studies were searched in Embase, PubMed, and ClinicalTrials.gov databases. To search for qualified studies, the following searching and screening criteria was used: (“homocysteine”) AND (“B vitamin” OR “folate” OR “B12” OR “B6”) AND (“osteoporosis” OR “osteoporotic” OR “fracture” OR “bone turnover”) AND (“randomized controlled trial” OR “RCT” OR “controlled trials”). To avoid missing any qualified studies, we performed a manual search of reference lists of included trials and relevant reviews. Trials were included regardless of publication status and language.

Inclusion and exclusion criteria

The trials included in this meta-analysis had to qualify simultaneously for the following criteria: (1) randomized controlled trials; and (2) studies comparing effect of B vitamin supplementation vs. placebo on fracture risk or bone turnover indicators. Studies meeting any the following criteria were excluded: (1) case report, animal study, or review; (2) studies with detailed outcome data (RR of fracture or changes of bone turnover) not extractable.

Data extraction

Two authors independently performed data extraction and data analysis. A third author was responsible for cross-checking the data. Disagreements were solved by discussion and consensus. Generally, the following information and data were extracted from the included trials: the family name of the first author, year of publication, features of patients included, number of participants, average age, sex, total plasma Hcy concentration at baseline, treatment (B vitamins used for supplementation and control), the period of intervention, outcome indicators measured, and whether there was significant Hcy reduction caused by the intervention. If the outcomes were reported with different units, unit conversion was performed before pooling the data.

Qualities assessment of trials included

Quality assessment of the trials was performed according to the recommendation of the Cochrane Handbook for Systematic Reviews of Interventions. Generally, 6 items were used to assess the bias of the RCTs: adequate sequence generation, allocation concealment, blinding, incomplete outcome data addressed, free of selective reporting, and free of other bias. The bias risk was reported as low risk of bias or high risk of bias.

Statistical analysis

Data integration and analysis were performed using Review Manager 5.3 (the Cochrane Collaboration). The risk ratio (RR) and corresponding 95% confidence intervals (CI) of fracture (intervention vs. control) were pooled for overall estimation. As to the changes of bone turnover indicators (continuous data), weighted mean difference (WMD) and corresponding 95% (CI) were pooled for overall estimation. Chi-square based Q test and I² value were used to assess between study heterogeneity, which were also used to determine the methods used for making estimation. A random effect model (DerSimonian and Laird method) was used for data analysis.
Four RCTs with 329 participants assessed the change of bone formation markers after B vitamin supplementation [13,14,19,20]. One study [13] gave patients folate, B6, and B12 simultaneously. 1 study [19] used both folate and VB12, 1 study [14] provided VB6 and VB12, and 1 study [20] only provided folate. Although the combination of B vitamins varied in different studies, all of them reported that the intervention significantly reduced plasma Hcy. Bone formation marker (ALP) and resorption markers (CTX) were used to assess the effect of B vitamin supplementation on bone turnover. Generally, compared with placebo, supplementation of B vitamins had no significant effect on ALP (WMD: −0.96, 95%CI: −4.10 to 2.18, p=0.55, I²=0%) (Figure 4A) and CTX (WMD: −0.01, 95%CI: −0.06 to 0.07, p=0.87, I²=0%) (Figure 4B). Salari et al. [20] study measured urine CTX instead of serum CTX and their results also showed that folate supplementation could not change urine CTX (supplementation vs. placebo, p=0.285).

Discussion

Homocystinuria, a disease characterized as high plasma homocysteine, usually contributes to distributed bone collagen profiles due to attachment of Hcy [23], leading to altered bone collagen fibers and fragile bones. Several epidemiological studies observed that increased plasma homocysteine concentration was associated with a higher incidence of osteoporotic fractures [6,24]. Several observational studies found that high plasma total Hcy level is a potential risk factor of osteoporotic fractures. The underlying mechanisms between plasma Hcy levels and fractures are uncertain. The potential mechanisms include the regulatory role of Hcy on bone tissue quality through altering the properties of collagen crosslink [25], affecting bone resorption by stimulating osteoclast formation and activity [26], and inducing mitochondrial dysfunction [27].
Table 1. Key characteristics of the RCTs included.

| Study               | Participants | No. participants | Age (mean) | Women (%) | Treatment | Baseline Hcy (μmol) | Intervention period | Outcome measured | Significant Hcy reduction by intervention? |
|---------------------|--------------|------------------|------------|-----------|-----------|--------------------|--------------------|------------------|------------------------------------------|
| Green 2007          | Age ≥65 y    | 68/67            | 74.1/74.6  | 60%/43%   | 1 mg folate + 0.5 mg VB12 daily | Placebo            | 19.7/19.3         | 24 months       | Plasma Hcy; Serum ALP; Serum-CTX           | Yes                                      |
| Keser 2013          | Women, age ≥65 y | 17/14          | 75.4/75.1  | 100%/100% | 0.8 mg folate + 1 mg VB12 daily | Placebo            | 13.7/16.0         | 4 months        | Plasma Hcy; Serum ALP; Serum-CTX           | Yes                                      |
| Salari 2014         | Postmenopausal osteoporotic women | 17/14          | 63.8/64.2  | 100%/100% | 1 mg folate daily | Placebo            | 11.7/14.1         | 6 months        | Plasma Hcy; osteocalcin; Serum ALP; urine-CTX | Yes                                      |
| Shahab-Ferdows 2012 | Nonpregnant and nonlactating women | 70/62          | 39.3/35.5  | N.A.      | 1 mg VB6 + 0.5 mg VB12 daily | Placebo            | 11.3/10.4         | 3 month         | Plasma Hcy; Serum ALP                        | Yes                                      |
| Sato 2005           | Ischemic stroke | 314/314         | 71.6/71.2  | 54%/54%   | 5 mg folate + 1.5 mg VB12 daily | Placebo            | 19.9/19.9         | 24 months       | Plasma Hcy; RR of fracture                   | Yes                                      |
| Sawka 2007          | Vascular disease or diabetes | 2758/2764     | 68.8/68.9  | 29%/28%   | 2.5 mg folate + 1 mg VB12 daily | Placebo            | 12.2/12.2         | 60 months       | Plasma Hcy; RR of fracture                   | Yes                                      |
| Armitage 2010       | Myocardial infarction | 6033/6031     | 64/64      | 17%/17%   | 2 mg folate + 1 mg VB12 daily | Placebo            | 13.5/13.5         | 60 months       | Plasma Hcy; RR of fracture                   | Yes                                      |
| Gommans 2013        | Stroke or TIA | 4089/4075       | 62.5/62.6  | 36%/36%   | 2 mg folate + 0.5 mg VB12 daily | Placebo            | 14.4/14.2         | 3.4 years        | Plasma Hcy; RR of fracture                   | Yes                                      |

Hcy – homocysteine; TIA – transient ischemic attack; ALP – alkaline phosphatase; CTX – β cross laps; VB6 – vitamin B6; VB12 – vitamin B12; I – intervention; C – control; RR – risk ratio; N.A. – not available.
B vitamins play quite important roles in Hcy metabolism. The effect of B vitamins supplementation on Hcy lowering has been well recognized. Folic acid supplementation could lower approximately 25% of plasma homocysteine, while vitamins B12 and B6 also have additional homocysteine-lowering effects [28,29]. However, it is not clear if Hcy-lowering therapy by folic acid, vitamins B6, or B12 supplementation is helpful in reducing the risk of fracture. In fact, Hcy is considered as a risk factor of cardiovascular and cerebrovascular risks and several RCTs were performed to assess the effect of lowering Hcy on stroke risk [15–18]. Considering the putative important role of Hcy in osteoporosis, these RCTs also explored the effect of B vitamin supplementation on the risk of fracture. However, due to lower occurrence rate and small number of fracture events, some of the trials were without sufficient statistical power to detect the potential beneficial effect [18]. Therefore, it was necessary to make a meta-analysis by pooling previous studies and to make an integrated estimation.

### Table 1: Meta-analysis of the effect of B vitamin supplementation on fracture risk.

| Study or subgroup | Supplementation | Control | Risk ratio |
|-------------------|-----------------|---------|------------|
|                   | Supplementation | Control | M-H, fixed, 95% CI |
|                   | Events Total    | Events Total | Weight |
| 1.1. Plasma Hcy <15 µmol/L | 253 6033 | 242 6031 | 45.9% | 1.05 [0.88, 1.24] |
| Armitage 2010     | 67 4089 | 78 4075 | 14.8% | 0.86 [0.62, 1.18] |
| Gommans 2013      | 175 2758 | 175 2764 | 32.3% | 1.00 [0.82, 1.23] |
| Sawka 2007        | 12880 | 12880 | 93.9% | 1.00 [0.89, 1.13] |
| Total (95% CI)    | 495 | 495 | |
| Heterogeneity: Chi²=1.14, df=2 (P=0.57); I²=0% |
| Test for overall effect: Z=0.00 (P=1.00) |
| 1.2. Plasma Hcy >15 µmol/L | 8 314 | 32 314 | 6.1% | 0.25 [0.12, 0.53] |
| Sato 2005         | 314 | 314 | 6.1% | 0.25 [0.12, 0.53] |
| Total (95% CI)    | 593 | 527 | |
| Heterogeneity: Not applicable |
| Test for overall effect: Z=3.58 (P=0.00003) |

### Table 2: Meta-analysis of the effect of B vitamin supplementation on bone turnover.

#### A: Bone formation marker (ALP).

| Study or subgroup | Supplementation | Control | Mean difference IV, fixed, 95% CI |
|-------------------|-----------------|---------|----------------------------------|
|                   | Mean SD Total   | Mean SD Total | Weight |
| Green 2007        | 0.5 7.1 68     | 1.3 13.2 67 | 76.9% | -0.80 [-4.38, 27.8] |
| Keser 2013        | 7.2 16 17    | 10.2 24.8 14 | 4.4% | -3.00 [-18.05, 12.05] |
| Safari 2014       | 1.8 10.3 17  | 3.3 13.8 14 | 12.9% | -1.50 [-10.23, 7.32] |
| Shahab-Ferdows 2012 | 0.6 42.2 70 | 34.1 62 | 5.8% | -0.40 [-13.43, 12.63] |
| Total (95% CI)    | 1.72 | 157 | 100.0% | -0.96 [-4.10, 2.18] |
| Heterogeneity: Chi²=0.10, df=3 (P=0.99); I²=0% |
| Test for overall effect: Z=0.70 (P=0.55) |

#### B: Resorption markers (CTX).

| Study or subgroup | Supplementation | Control | Mean difference IV, fixed, 95% CI |
|-------------------|-----------------|---------|----------------------------------|
|                   | Mean SD Total   | Mean SD Total | Weight |
| Green 2007        | 0.04 0.26 68 | 0.05 0.24 67 | 61.1% | -0.01 [-0.09, 0.07] |
| Keser 2013        | 0.05 0.12 17 | 0.02 0.17 14 | 38.9% | 0.03 [-0.08, 0.14] |
| Total (95% CI)    | 0.85 | 81 | 100.0% | 0.01 [-0.06, 0.07] |
| Heterogeneity: Chi²=0.34, df=1 (P=0.56); I²=0% |
| Test for overall effect: Z=0.17 (P=0.87) |
Based on results of 4 RCTs, this meta-analysis failed to identify any risk-reducing effect of daily supplementation of B vitamins on osteoporotic fracture in patients with vascular disease and with relatively normal plasma Hcy.

Although previous in vitro and in vivo studies observed a stimulatory effect of mildly elevated homocysteine on osteoclastic activity and a positive correlation between plasma Hcy and markers of bone resorption [30–32], few studies have examined the association between bone turnover markers and homocysteine-lowering intervention. The individual RCTs lack statistical power due to the small number of participants in experimental and control groups. Based on pooling the results of the 4 RCTs, this meta-analysis did not find any positive effect of B vitamin supplementation on bone turnover.

Although the number of studies included is relatively small, the sample size of the included studies, especially those that assessed B vitamin supplementation on fracture risks, is large. Thus, the statistical power of the findings is strong. However, the present study also has several limitations. Firstly, the baseline of the patients included varied significantly in some studies. For example, the mean baseline folate level of the participants in the HOPE2 study [16] was approximately 5 times higher than the participants in Sato’s study in Japan [15]. Therefore, it might be possible that B vitamin supplementation might not generate additional benefits for the patients who already have high serum B vitamin level. Among the 4 RCTs that assessed B vitamin supplementation and fractures, only Sato’s study observed a risk-reduction effect. In fact, the study population was highly selected and characterized as very high plasma Hcy level, severe disability, and an unusually (10-fold) high fracture risk rate of the control cases compared to the average Japanese population of the same age [21]. However, a recent meta-analysis observed that fortification with certain B vitamins, such as folate, exert protective effects on Hcy-related cerebrovascular risks and additional supplementation thus had no additive effect [33]. Therefore, we cannot exclude the possibility that B vitamin supplementation might have some protective effects on bone health due to the homocysteine-lowering effects in countries without folate fortification, such as Japan.

Conclusions

This meta-analysis failed to identify any risk-reducing effect of daily supplementation with B vitamins (single or combined use of folate, B6, and B12) on osteoporotic fracture in patients with vascular disease and with relatively normal plasma Hcy. In addition, we also did not observe any positive effects of B vitamin supplementation on bone turnover. However, the possible benefits in certain populations, such as populations with very high plasma Hcy and from regions without B vitamin fortification, should be explored in the future.

Conflict of interest

The authors had no conflict of interest.

References:

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA, 2001; 285: 785–95
2. Melton Li III: Adverse outcomes of osteoporotic fractures in the general population. J Bone Mineral Res, 2003; 18: 1139–41
3. Govindarajan P, Schleowitz G, Schliefeke N et al: Implications of combined ovariectomy/multi-deficiency diet on rat bone with age-related variation in bone parameters and bone loss at multiple skeletal sites by DEXA. Med Sci Monit Basic Res, 2013; 19: 76–86
4. Kanis JA, McCloskey EV, Johansson H et al: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int, 2013; 24: 23–57
5. Raizu LG: Homocysteine and osteoporotic fractures – culprit or bystander? N Engl J Med, 2004; 350: 2089–90
6. Kim BI, Koh JM, Ahn SH et al: High serum total homocysteine levels accelerate hip bone loss in healthy premenopausal women and men. Bone, 2013; 52: 56–62
7. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM et al: Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med, 2004; 350: 2033–41
8. Yang J, Hu X, Zhang Q et al: Homocysteine level and risk of fracture: A meta-analysis and systematic review. Bone, 2012, 51: 376–82
9. Levasseur R: Bone tissue and hyperhomocysteinemia. Joint Bone Spine, 2009; 76: 234–40
10. McLean RR, Jacques PF, Selhub J et al: Plasma B vitamins, homocysteine, and their relation with bone loss and hip fracture in elderly men and women. J Clin Endocrinol Metab, 2008; 93: 2206–12
11. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists’ Collaboration. BMJ, 1998; 316: 894–98
12. Clarke M, Ward M, Strain JI et al: B-vitamins and bone in health and disease: the current evidence. Proc Nutr Soc, 2014; 73: 330–39
13. Green TJ, McMahon JA, Skeaff CM et al: Lowering homocysteine with B vitamins has no effect on biomarkers of bone turnover in older persons: a 2-y randomized controlled trial. Am J Clin Nutr, 2007; 85: 460–64
14. Shahab-Ferdows S, Anaya-Loyola MA, Vergara-Castaneda H et al: Vitamin B-12 supplementation of rural Mexican women changes biochemical vitamin B-12 status indicators but does not affect hematology or a bone turnover marker. J Nutr, 2012; 142: 1881–87
15. Sato Y, Honda Y, Iwamoto J et al: Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA, 2005; 293: 1082–88
16. Sawka AM, Ray JG, Yi Q et al: Randomized clinical trial of homocysteine lowering therapy and fractures. Arch Intern Med, 2007; 167: 2136–39
17. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage JM, Bowman L, Clarke RJ et al: Effects of homocysteine-lowering with folic acid plus vitamin B12 vs. placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA, 2010; 303: 2486–94
18. Gomans J, Yi Q, Elkeboom JW et al: The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: study of VITATOPS, a randomised placebo-controlled trial. BMC Geriatr, 2013; 13: 88
19. Keser I, Ilich JZ, Vrkic N et al: Folic acid and vitamin B(12) supplementation lowers plasma homocysteine but has no effect on serum bone turnover markers in elderly women: a randomized, double-blind, placebo-controlled trial. Nutr Res, 2013; 33: 211–19

20. Salari P, Abdollahi M, Heshmat R et al: Effect of folic acid on bone metabolism: a randomized double blind clinical trial in postmenopausal osteoporotic women. Daru, 2014; 22: 62

21. Morris MS, Jacques PF, Selhub J: Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone, 2005; 37: 234–42

22. Balogh E, Bereczky Z, Katona E et al: Interaction between homocysteine and lipoprotein(a) increases the prevalence of coronary artery disease/myocardial infarction in women: a case-control study. Thromb Res, 2012; 129: 133–38

23. Lubec B, Fang-Kircher S, Lubec T et al: Evidence for McKusick’s hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta, 1996; 1315: 159–62

24. Perez-Castrillon JL, Arranz-Pena ML, Luis DD: Homocysteine as a predictive factor for hip fracture in older persons. New Engl J Med, 2004; 351: 1027–30; author reply 1027–30

25. Saito M, Fujii K, Marumo K: Degree of mineralization-related collagen cross-linking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int, 2006; 79: 160–68

26. Herrmann M, Widmann T, Herrmann W: Homocysteine – a newly recognised risk factor for osteoporosis. Clin Chem Lab Med, 2005; 43: 1111–17

27. Kalani A, Kamat PK, Voor MJ et al: Mitochondrial epigenetics in bone remodeling during hyperhomocysteinemia. Mol Cell Biochem, 2014; 395: 89–98

28. Clarke R: Lowering blood homocysteine with folic acid-based supplements: meta-analysis of randomised trials. Indian Heart J, 2000; 52: 559–64

29. McKinley MC, McNulty H, McPartlin J et al: Low-dose vitamin B-6 effective-ly lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr, 2001; 73: 759–64

30. Herrmann M, Widmann T, Colaianni G et al: Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem, 2005; 51: 2348–53

31. Kim DJ, Koh JM, Lee O et al: Homocysteine enhances apoptosis in human bone marrow stromal cells. Bone, 2006; 39: 582–90

32. Herrmann M, Kraenzlin M, Pape G et al: Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women. Clin Chem Lab Med, 2005; 43: 1118–23

33. Zeng R, Xu CH, Xu YN et al: The effect of folate fortification on folic acid-based homocysteine-lowering intervention and stroke risk: a meta-analysis. Publ Health Nutr, 2014; 1–8 [Epub ahead of print]